Headquartered in Parsippany, NJ Fiscal year ends September NASDAQ: EMBC embecta.com
Embecta Corp. is a global diabetes care company that specializes in insulin delivery devices. The company's product portfolio includes pen needles, syringes, safety injection devices, swabs, and accessories. Following its 2022 separation from Becton, Dickinson and Company (BD), embecta has been building independent operations including global ERP implementation and brand transition. The company recently expanded its portfolio through the acquisition of Owen Mumford Holdings Limited, adding contract manufacturing capabilities and complementary medical device products. Embecta is also pursuing growth through B2B co-packaging partnerships for GLP-1 therapies, with launches in India, Canada, and Brazil, and a planned U.S. launch. The company employs approximately 2,000 people globally and trades on Nasdaq under the ticker EMBC. It carries significant leverage with approximately $1.469 billion in debt principal outstanding and negative shareholders' equity. Updated
Expedia is sending shareholders about $55 million, at 48 cents a share, with the money arriving September 17. Prospect Capital, Solstice Advanced Materials, Kamada and Embecta are paying out today's group too. You need to own the shares today to get paid.
Embecta Corp. is a global diabetes care company that specializes in insulin delivery devices. The company's product portfolio includes pen needles, syringes, safety injection devices, swabs, and accessories.
The Wall Street consensus 12-month price target for EMBC is $4.00.
